Alcon Q2 FY26 operating income drops 96% to $11 million; net sales rise 8% to $2.78 billion

• Alcon net sales rose 8% to $2.78 billion in Q2 2026.
• Operating income plunged 96% to $11 million, turning net income attributable to shareholders to no profit from a year earlier.
• Research and development expense jumped 171% to $663 million on a $505 million impairment tied to discontinuing the PowerVision programs.
• Vision Care segment contribution climbed 36% to $283 million, while Surgical segment contribution rose 4% to $392 million.
• First-half net sales increased 9% to $5.47 billion, while operating income fell 58% to $303 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alcon AG published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.